Rehm J, Shield KD (2019) Global burden of disease and the impact of mental and addictive disorders. Curr Psychiatry Rep 21:1–7
WHO (2018) Management of physical health conditions in adults with severe mental disorders: WHO guidelines
Carr VJ, Neil AL, Halpin SA, Holmes S, Lewin TJ (2003) Costs of schizophrenia and other psychoses in urban Australia: findings from the low prevalence (psychotic) disorders Study. Australian New Z J Psychiatry 37(1):31–40
Druss BG, Bradford DW, Rosenheck RA, Radford MJ, Krumholz HM (2000) Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA 283(4):506–511
Article PubMed CAS Google Scholar
Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M (2017) Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 4(4):295–301
Liu NH, Daumit GL, Dua T, Aquila R, Charlson F, Cuijpers P et al (2017) Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry 16(1):30–40
Article PubMed PubMed Central CAS Google Scholar
Fekadu A, Medhin G, Kebede D, Alem A, Cleare AJ, Prince M et al (2015) Excess mortality in severe mental illness: 10-year population-based cohort study in rural Ethiopia. Br J Psychiatry 206(4):289–296
Giref AZ (2008) Economic burden of schizophrenia and bipolar disorders in ethiopia. A Dissertation
Moller MD, Murphy MF (1997) The Three R’s Rehabilitation Program: a prevention approach for the management of relapse symptoms associated with psychiatric diagnoses. Psychiatr Rehabil J 20(3):42
Gleeson JF, Alvarez-Jimenez M, Cotton SM, Parker AG, Hetrick S (2010) A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr Res 119(1–3):79–88
Csernansky JG, Schuchart EK (2002) Relapse and rehospitalisation rates in patients with schizophrenia. CNS Drugs 16(7):473–484
Hogarty GE, Ulrich RF (1998) The limited effects of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 32(3–4):243–250
Article PubMed CAS Google Scholar
Moncrieff J (2006) Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica 114(1):3–13
Article PubMed CAS Google Scholar
Morken G, Widen JH, Grawe RW (2008) Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 8(1):32
Article PubMed PubMed Central Google Scholar
Munro J, Osborne S, Dearden L, Pascoe K, Gauthier A, Price M (2011) Hospital treatment and management in relapse of schizophrenia in the UK: associated costs. Psychiatrist 35(3):95–100
Drake R, Mercer-McFadden C, Mueser K, McHugo G, Bond G (2000) Review of integrated mental health and substance abuse treatment for patients with dual disorders. Year Book Psychiatry Appl Mental Health 2000(1):139–140
Gregg L, Barrowclough C, Haddock G (2007) Reasons for increased substance use in psychosis. Clin Psychol Rev 27(4):494–510
Wade D, Harrigan S, Edwards J, Burgess P, Whelan G, McGorry P (2006) Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry 189(3):229–234
Article PubMed CAS Google Scholar
Altamura A, Bassetti R, Sassella F, Salvadori D, Mundo E (2001) Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study. Schizophr Res 52(1–2):29–36
Article PubMed CAS Google Scholar
Cechnicki A, Hanuszkiewicz I, Polczyk R, Bielańska A (2011) Prognostic value of duration of untreated psychosis in long-term outcome of schizophrenia. Med Sci Monitor: Int Med J Experimental Clin Res 17(5):CR277
Owens DC, Johnstone EC, Miller P, Macmillan JF, Crow TJ (2010) Duration of untreated illness and outcome in schizophrenia: test of predictions in relation to relapse risk. Br J Psychiatry 196(4):296–301
Buckley PF, Miller BJ, Lehrer DS, Castle DJ (2009) Psychiatric comorbidities and schizophrenia. Schizophr Bull 35(2):383–402
Dernovšek MZ, Šprah L (2009) Comorbid anxiety in patients with psychosis. Psychiatria Danubina 21(1):43–50
Kozumplik O, Uzun S, Jakovljević M (2009) Psychotic disorders and comorbidity: somatic illness vs. side effect. Psychiatria Danubina 21(3):361–367
Almond S, Knapp M, Francois C, Toumi M, Brugha T (2004) Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 184(4):346–351
Davies T (1994) Psychosocial factors and relapse of schizophrenia. British Medical Journal Publishing Group
Pennington M, McCrone P (2017) The cost of relapse in schizophrenia. PharmacoEconomics 35(9):921–936
Edition F (2013) Diagnostic and statistical manual of mental disorders. Am Psychiatric Assoc
Dalgard OS The Oslo 3-items social support scale. 20002
Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG (2001) The alcohol use disorders identification test. World Health Organization Geneva
Boyd JE, Otilingam PG, DeForge BR (2014) Brief version of the internalized stigma of Mental Illness (ISMI) scale: psychometric properties and relationship to depression, self esteem, recovery orientation, empowerment, and perceived devaluation and discrimination. Psychiatr Rehabil J 37(1):17
Amenson C (1998) Family skills for relapse prevention. Pacific Clinics Institute, Pasadena, CA
Wiersma D, Nienhuis FJ, Slooff CJ, Giel R (1998) Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 24(1):75–85
Article PubMed CAS Google Scholar
Üçok A, Polat A, Çakır S, Genç A (2006) One year outcome in first episode schizophrenia: predictors of relapse. Eur Arch Psychiatry Clin NeuroSci 256:37–43
Addington D, Jean Addington M, Patten S (2007) Relapse rates in an early psychosis treatment service. Acta Psychiatrica Scandinavica 115(2):126–131
Article PubMed CAS Google Scholar
Bergé D, Mané A, Salgado P, Cortizo R, Garnier C, Gomez L et al (2016) Predictors of relapse and functioning in first-episode psychosis: a two-year follow-up study. Psychiatric Serv 67(2):227–233
Mi W-F, Chen X-M, Fan T-T, Tabarak S, Xiao J-B, Cao Y-Z et al (2020) Identifying modifiable risk factors for relapse in patients with schizophrenia in China. Front Psychiatry 11:574763
Article PubMed PubMed Central Google Scholar
Benjet C, Albor YC, Bocanegra ES, Borges G, Méndez E, Casanova L et al (2020) Incidence and recurrence of depression from adolescence to early adulthood: a longitudinal follow-up of the Mexican adolescent mental health survey. J Affect Disord 263:540–546
Bioque M, Mezquida G, Amoretti S, García-Rizo C, López-Ilundain JM, Diaz-Caneja CM et al (2022) Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia. Schizophr Res 243:32–42
Di Capite S, Upthegrove R, Mallikarjun P (2018) The relapse rate and predictors of relapse in patients with first-episode psychosis following discontinuation of antipsychotic medication. Early Interv Psychiat 12(5):893–899
Schennach R, Obermeier M, Meyer S, Jäger M, Schmauss M, Laux G et al (2012) Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatric Serv 63(1):87–90
留言 (0)